Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mucosal immunity during pollen allergen immunotherapy
NL-OMON61614Not yet recruiting
- Sponsor
- Rijnstate
- Start
- Jan 2027
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of phleum pratense allergen extract, travoprost and Olea europaea allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (3 arms), sponsored by Rijnstate. Primary endpoint: Longitudinal within-patient changes in nasal mucosal inflammatory biomarkers. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
phleum pratense allergen extracttravoprostOlea europaea allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NL-OMON61614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61614.